Furthermore, our observations highlight SETD2/H3K36me3 deficiency as a reversible, and druggable mechanism of genetic instability that operates independently of BCR::ABL1, potentially contributing to disease progression in CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.